{"id":554764,"date":"2025-10-31T00:00:00","date_gmt":"2025-10-31T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0001-2025-biopharma-chronic-kidney-disease-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-03-31T10:24:34","modified_gmt":"2026-03-31T10:24:34","slug":"dlsfmd0001-2026-biopharma-chronic-kidney-disease-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0001-2026-biopharma-chronic-kidney-disease-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Chronic Kidney Disease &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Chronic kidney disease (<abbr title=\"chronic kidney disease\">CKD<\/abbr>) encompasses a set of heterogeneous disorders that gradually damage the kidneys\u2019 structure or function. To manage <abbr title=\"chronic kidney disease\">CKD<\/abbr> and delay its progression to end-stage kidney disease, antihypertensive agents and <abbr title=\"sodium-glucose co-transporter-2\">SGLT-2<\/abbr> inhibitors are commonly prescribed. <abbr title=\"renin-angiotensin-aldosterone system\">RAAS<\/abbr> inhibitors have long been the cornerstone of <abbr title=\"chronic kidney disease\">CKD<\/abbr> treatment, while <abbr title=\"sodium-glucose co-transporter-2\">SGLT-2<\/abbr> inhibitors, such as AstraZeneca\u2019s Farxiga and Eli Lilly\u2019s Jardiance, are becoming the standard of care. Bayer\u2019s Kerendia (a mineralocorticoid receptor antagonist) and Novo Nordisk&#8217;s semaglutide (a <abbr title=\"glucagon-like peptide\">GLP<\/abbr>-1 receptor antagonist) are both approved for <abbr title=\"chronic kidney disease\">CKD<\/abbr> patients with type 2 diabetes, with Kerendia further being evaluated for potential use in nondiabetic <abbr title=\"chronic kidney disease\">CKD<\/abbr>. We expect the <abbr title=\"chronic kidney disease\">CKD<\/abbr> therapy market to grow over the 2024-2034 forecast period, driven by an increase in diagnosed <abbr title=\"chronic kidney disease\">CKD<\/abbr> cases and emerging therapies such as ProKidney\u2019s rilparencel and various combination therapies. Despite the availability of medications that can delay the progression of <abbr title=\"chronic kidney disease\">CKD<\/abbr>, no therapy has been proven to halt or reverse disease progression, leaving a significant unmet need in <abbr title=\"chronic kidney disease\">CKD<\/abbr> treatment.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Does the inclusion of cardiovascular endpoints in clinical trials of <abbr title=\"chronic kidney disease\">CKD<\/abbr> therapies confer a competitive advantage?<\/li>\n<li>What do key opinion leaders consider the advantages and disadvantages of current therapies?<\/li>\n<li>What is the commercial opportunity for emerging therapies? What are the thoughts of key opinion leaders on emerging therapies?<\/li>\n<li>What market access and reimbursement challenges will the emerging <abbr title=\"chronic kidney disease\">CKD<\/abbr> therapies face in the G7? How will these challenges influence their uptake?<\/li>\n<\/ul>\n<p><strong>Geography: <\/strong>United States, France, Germany, Italy, Spain, United Kingdom, and Japan<\/p>\n<p><strong>Primary research: <\/strong>Country-specific interviews with thought-leading nephrologists. Supported by survey data collected for this and other Clarivate research.<\/p>\n<p><strong>Epidemiology: <\/strong>Diagnosed prevalence of <abbr title=\"chronic kidney disease\">CKD<\/abbr> by country and stage of disease.<\/p>\n<p><strong>Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key <abbr title=\"chronic kidney disease\">CKD<\/abbr> therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations.<\/p>\n<p><strong>Drug treatments: <\/strong>Coverage of key current and emerging therapies.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p style=\"\">Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul>\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-554764","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-kidney-disease","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/554764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/554764\/revisions"}],"predecessor-version":[{"id":575299,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/554764\/revisions\/575299"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=554764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}